Androgens and the Lipogenic Switch in Prostate Cancer

  • Johannes V. Swinnen
  • Koen Brusselmans
  • Hannelore V. Heemers
  • Guido Verhoeven


Androgens have a major impact on prostate cancer cell biology and modulate a variety of key cellular processes and functions. One of the processes that are most strikingly affected is lipid biosynthesis. Through a unique indirect mechanism that involves activation of the lipogenic transcription factor SREBP, androgens coordinately stimulate the expression of more than 20 enzymes involved in lipid synthesis, and in this way they affect the entire lipogenic program in prostate cancer cells. Through additional mechanisms, including the stimulation of an ubiquitin-specific protease that removes the degradation-tag ubiquitin from lipogenic enzymes such as fatty acid synthase, an even more complex network of regulatory control is created. Progressive deregulation of this network results in a marked overexpression of lipogenic enzymes, referred to as the lipogenic switch. This switch typically accompanies the development and progression of prostate cancer and is thought to play an active role in prostate cancer cell biology. In fact, interference with the lipogenic process impairs proper membrane formation and functioning, halts cell proliferation, and induces cell death selectively in cancer cells. These findings suggest that enhanced lipogenesis in cancer cells is an essential trait of prostate cancer progression and is a promising novel target for antineoplastic intervention.


Androgen Receptor Prostate Cancer Cell Fatty Acid Synthesis Lipogenic Enzyme Induce Growth Arrest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors are supported by a grant “Concerted Research Action” by the K.U. Leuven and by research grants from the Research Foundation-Flanders (FWO) (Belgium). K. Brusselmans is a postdoctoral fellow of the Research Foundation-Flanders (FWO) (Belgium).


  1. Bandyopadhyay S, Pai SK, Watabe M, Gross SC, Hirota S, Hosobe S, Tsukada T, Miura K, Saito K, Markwell SJ, Wang Y, Huggenvik J, Pauza ME, Iiizumi M, Watabe K (2005) FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 24: 5389–5395.PubMedCrossRefGoogle Scholar
  2. Bandyopadhyay S, Zhan R, Wang Y, Pai SK, Hirota S, Hosobe S, Takano Y, Saito K, Furuta E, Iiizumi M, Mohinta S, Watabe M, Chalfant C, Watabe K (2006) Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res 66: 5934–5940.PubMedCrossRefGoogle Scholar
  3. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB (2005) ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24: 6314–6322.PubMedCrossRefGoogle Scholar
  4. Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, Verhoeven G, Swinnen JV (2007) Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 67: 8180–8187.PubMedCrossRefGoogle Scholar
  5. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, et al. (1993) Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53: 3869–3873.PubMedGoogle Scholar
  6. Brown MS, Ye J, Rawson RB, Goldstein JL (2000) Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100: 391–398.PubMedCrossRefGoogle Scholar
  7. Brusselmans K, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV (2003) Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 106: 856–862.PubMedCrossRefGoogle Scholar
  8. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV (2005a) RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65: 6719–6725.CrossRefGoogle Scholar
  9. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV (2005b) Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 280: 5636–5645.CrossRefGoogle Scholar
  10. Brusselmans K, Timmermans L, Van de Sande T, Van Veldhoven PP, Guan G, Shechter I, Claessens F, Verhoeven G, Swinnen JV (2007) Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation. J Biol Chem 282: 18777–18785.PubMedCrossRefGoogle Scholar
  11. Bull JH, Ellison G, Patel A, Muir G, Walker M, Underwood M, Khan F, Paskins L (2001) Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 84: 1512–1519.PubMedCrossRefGoogle Scholar
  12. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V (2006) Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 66: 5287–5294.PubMedCrossRefGoogle Scholar
  13. Chakravarthy MV, Zhu Y, López M, Yin L, Wozniak DF, Coleman T, Hu Z, Wolfgang M, Vidal-Puig A, Lane MD, Semenkovich CF (2007) Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis. J Clin Invest 117: 2539–2552.PubMedCrossRefGoogle Scholar
  14. Chalbos D, Joyeux C, Galtier F, Escot C, Chambon M, Maudelonde T, Rochefort H (1990) Regulation of fatty acid synthetase by progesterone in normal and tumoral human mammary glands. Rev Esp Fisiol 46: 43–46.PubMedGoogle Scholar
  15. Chambon M, Rochefort H, Vial HJ, Chalbos D (1989) Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors. J Steroid Biochem 33: 915–922.PubMedCrossRefGoogle Scholar
  16. Clegg DJ, Wortman MD, Benoit SC, McOsker CC, Seeley RJ (2002) Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion. Diabetes 51: 3196–3201.PubMedCrossRefGoogle Scholar
  17. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV (2003) RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63: 3799–3804.PubMedGoogle Scholar
  18. Denoyelle C, Albanese P, Uzan G, Hong L, Vannier JP, Soria J, Soria C (2003) Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 15: 327–338.PubMedCrossRefGoogle Scholar
  19. Epstein JI, Carmichael M, Partin AW (1995) OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45: 81–86.PubMedCrossRefGoogle Scholar
  20. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC (2004) Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64: 2212–2221.PubMedCrossRefGoogle Scholar
  21. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M (2004) The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5: 253–261.PubMedCrossRefGoogle Scholar
  22. Hager MH, Solomon KR, Freeman MR (2006) The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 9: 379–385.PubMedCrossRefGoogle Scholar
  23. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N (2005) Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280: 32081–32089.PubMedCrossRefGoogle Scholar
  24. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8: 311–321.PubMedCrossRefGoogle Scholar
  25. Heemers H, Vanderhoydonc F, Heyns W, Verhoeven G, Swinnen JV (2000) Progestins and androgens increase expression of Spot 14 in T47-D breast tumor cells. Biochem Biophys Res Commun 269: 209–212.PubMedCrossRefGoogle Scholar
  26. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G, Swinnen JV (2001) Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 15: 1817–1828.PubMedCrossRefGoogle Scholar
  27. Heemers H, Vanderhoydonc F, Roskams T, Shechter I, Heyns W, Verhoeven G, Swinnen JV (2003) Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Mol Cell Endocrinol 205: 21–31.PubMedCrossRefGoogle Scholar
  28. Heemers H, Verrijdt G, Organe S, Claessens F, Heyns W, Verhoeven G, Swinnen JV (2004) Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the androgen receptor. J Biol Chem 279: 30880–30887.PubMedCrossRefGoogle Scholar
  29. Heemers HV, Verhoeven G, Swinnen JV (2006) Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Mol Endocrinol 20: 2265–2277.PubMedCrossRefGoogle Scholar
  30. Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P (2002) Going malignant: the hypoxia-cancer connection in the prostate. Bioessays 24: 749–757.PubMedCrossRefGoogle Scholar
  31. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125–1131.PubMedGoogle Scholar
  32. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648–657.PubMedCrossRefGoogle Scholar
  33. Joyeux C, Rochefort H, Chalbos D (1989) Progestin increases gene transcription and messenger ribonucleic acid stability of fatty acid synthetase in breast cancer cells. Mol Endocrinol 10: 681–686.CrossRefGoogle Scholar
  34. Kinlaw WB, Quinn JL, Wells WA, Roser-Jones C, Moncur JT (2006) Spot 14: a marker of aggressive breast cancer and a potential therapeutic target. Endocrinology 147: 4048–4055.PubMedCrossRefGoogle Scholar
  35. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64: 2070–2075.PubMedCrossRefGoogle Scholar
  36. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR (1994) Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 91: 6379–6383.PubMedCrossRefGoogle Scholar
  37. Kuhajda FP (2000) fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202–208.PubMedCrossRefGoogle Scholar
  38. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 97: 3450–3454.PubMedCrossRefGoogle Scholar
  39. Lacasa D, Le Liepvre X, Ferre P, Dugail I (2001) Progesterone stimulates adipocyte determination and differentiation factor 1/sterol regulatory element-binding protein 1c gene expression. Potential mechanism for the lipogenic effect of progesterone in adipose tissue. J Biol Chem 276: 11512–11516.PubMedCrossRefGoogle Scholar
  40. Li BH, Tian WX (2004) Inhibitory effects of flavonoids on animal fatty acid synthase. J Biochem (Tokyo) 135: 85–91.CrossRefGoogle Scholar
  41. Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ (2007) Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 67: 1262–1269.PubMedCrossRefGoogle Scholar
  42. Liu B, Wang Y, Fillgrove KL, Anderson VE (2002) Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother Pharmacol 49: 187–193.PubMedCrossRefGoogle Scholar
  43. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP (2000) Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288: 2379–2381.PubMedCrossRefGoogle Scholar
  44. Lu S, Archer MC (2005) Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis 26: 153–157.PubMedCrossRefGoogle Scholar
  45. Martel PM, Bingham CM, McGraw CJ, Baker CL, Morganelli PM, Meng ML, Armstrong JM, Moncur JT, Kinlaw WB (2006) S14 protein in breast cancer cells: direct evidence of regulation by SREBP-1c, superinduction with progestin, and effects on cell growth. Exp Cell Res 312: 278–288.PubMedGoogle Scholar
  46. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763–777.PubMedCrossRefGoogle Scholar
  47. Menendez JA, Vellon L, Colomer R, Lupu R (2005) Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer 115: 19–35.PubMedCrossRefGoogle Scholar
  48. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3: 2115–2120.PubMedGoogle Scholar
  49. Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C, Gifford D, Coleman I, Nelson PS (2005) Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int J Cancer 114: 563–571.PubMedCrossRefGoogle Scholar
  50. Myers RB, Oelschlager DK, Weiss HL, Frost AR, Grizzle WE (2001) Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol 165: 1027–1032.PubMedCrossRefGoogle Scholar
  51. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B (2002) The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 99: 11890–11895.PubMedCrossRefGoogle Scholar
  52. Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF (1998) Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 58: 4611–4615.PubMedGoogle Scholar
  53. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP (2000) Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60: 213–218.PubMedGoogle Scholar
  54. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB (2001) Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 47: 102–110.PubMedCrossRefGoogle Scholar
  55. Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J, Schulze A (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24: 6465–6481.PubMedGoogle Scholar
  56. Prowatke I, Devens F, Benner A, Grone EF, Mertens D, Grone HJ, Lichter P, Joos S (2007) Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer 96: 82–88.PubMedCrossRefGoogle Scholar
  57. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1: 707–715.PubMedGoogle Scholar
  58. Schmidt LC, Ballman KV, Tindall DJ (2007) Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Prostate 67: 1111–1120.PubMedCrossRefGoogle Scholar
  59. Segawa T, Nau ME, Xu LL, Chilukuri RN, Makarem M, Zhang W, Petrovics G, Sesterhenn IA, McLeod DG, Moul JW, Vahey M, Srivastava S (2002) Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 21: 8749–8758.PubMedCrossRefGoogle Scholar
  60. Shah US, Dhir R, Gollin SM, Chandran UR, Lewis D, Acquafondata M, Pflug BR (2006) Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol 37: 401–409.PubMedCrossRefGoogle Scholar
  61. Shurbaji MS, Kalbfleisch JH, Thurmond TS (1996) Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 27: 917–921.PubMedCrossRefGoogle Scholar
  62. Swinnen JV, Esquenet M, Heyns W, Rombauts W, Verhoeven G (1994) Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP. Mol Cell Endocrinol 104: 153–162.PubMedCrossRefGoogle Scholar
  63. Swinnen JV, VanVeldhoven PP, Esquenet M, Heyns W, Verhoeven G (1996) Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137: 4468–4474.PubMedCrossRefGoogle Scholar
  64. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G (1997a) Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57: 1086–1090.Google Scholar
  65. Swinnen JV, Ulrix W, Heyns W, Verhoeven G (1997b) Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc Natl Acad Sci U S A 94: 12975–12880.CrossRefGoogle Scholar
  66. Swinnen JV, Heemers H, Deboel L, Foufelle F, Heyns W, Verhoeven G (2000a) Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19: 5173–5181.CrossRefGoogle Scholar
  67. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, Van Poppel H, Baert L, Goossens K, Heyns W, Verhoeven G (2000b) Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 88: 176–179.CrossRefGoogle Scholar
  68. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98: 19–22.PubMedCrossRefGoogle Scholar
  69. Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W, Verhoeven G (2003) Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302: 898–903.PubMedCrossRefGoogle Scholar
  70. Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9: 358–365.PubMedCrossRefGoogle Scholar
  71. Szutowicz A, Kwiatkowski J, Angielski S (1979) Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br J Cancer 39: 681–687.PubMedCrossRefGoogle Scholar
  72. Thupari JN, Pinn ML, Kuhajda FP (2001) Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 285: 217–223.PubMedCrossRefGoogle Scholar
  73. Turyn J, Schlichtholz B, Dettlaff-Pokora A, Presler M, Goyke E, Matuszewski M, Kmiec Z, Krajka K, Swierczynski J (2003) Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer. Horm Metab Res 35: 565–569.PubMedCrossRefGoogle Scholar
  74. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV (2002) Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62: 642–646.PubMedGoogle Scholar
  75. Van de Sande T, Roskams T, Lerut E, Joniau S, Van Poppel H, Verhoeven G, Swinnen JV (2005) High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol 206: 214–219.PubMedCrossRefGoogle Scholar
  76. Wang X, Tian W (2001) Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Biophys Res Commun 288: 1200–1206.PubMedCrossRefGoogle Scholar
  77. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR (2005) Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24: 3574–3582.PubMedCrossRefGoogle Scholar
  78. Yahagi N, Shimano H, Hasegawa K, Ohashi K, Matsuzaka T, Najima Y, Sekiya M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Nagai R, Ishibashi S, Kadowaki T, Makuuchi M, Ohnishi S, Osuga J, Yamada N (2005) Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 41: 1316–1322.PubMedCrossRefGoogle Scholar
  79. Yeh CW, Chen WJ, Chiang CT, Lin-Shiau SY, Lin JK (2003) Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects. Pharmacogenomics J 3: 267–276.PubMedGoogle Scholar
  80. Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, Park BW, Kim KS (2007) Up-regulation of acetyl-CoA carboxylase {alpha} and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 282: 26122–26131.PubMedCrossRefGoogle Scholar
  81. Zhong WB, Wang CY, Chang TC, Lee WS (2003) Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 144: 3852–3859.PubMedCrossRefGoogle Scholar
  82. Zhou W, Han W, Landree LE, Thupari JN, Pinn ML, Bililign T, Kim EK, Vadlamudi A, Medghalchi SM, El Meskini R, Ronnett GV, Townsend CA, Kuhajda FP (2007) Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 67: 2964–2971.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Johannes V. Swinnen
    • 1
  • Koen Brusselmans
  • Hannelore V. Heemers
  • Guido Verhoeven
  1. 1.Katholieke Universiteit LeuvenLaboratory for Experimental Medicine and Endocrinology, Gasthuisberg O&N1Belgium

Personalised recommendations